DYN
Dyne Therapeutics, Inc.
$15.62
-0.95%
2026-10-23
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
-4.81
EPS (TTM)
$-3.26
ROE
-81.6%
Profit Margin
0.0%
Debt/Equity
33.23
Price/Book
3.78
Beta
1.08
Market Cap
$2.99B
Avg Volume (10D)
3.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$27.30
60D Low
$14.13
Avg Volume
2.8M
Latest Close
$15.62
Get breakout alerts for DYN
Sign up for Breakout Scanner to receive daily notifications when DYN triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Dyne Therapeutics, Inc. (DYN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DYN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DYN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.